AI-translated research papers aren't trustworthy — you can't rely on a machine translation of medical literature.

The platform publishes several AI-extracted research entries — Zozulya 2008 Selank, Kaplan 1996 Semax, Levitskaya 2008 Semax synthesis, Anisimov-Khavinson 2001 CBA mice, Anisimov 2002 Epitalon colon-cancer, Manchenko 2010 Semax routes, Khavinson Morozov 2003 NEL — all marked as agent-pipeline translations or extractions with explicit translator-confidence notes and accessibility flags. The objection comes up: should anyone trust an AI translation of medical literature?

The honest framing requires unpacking three different things the objection conflates.

1. "AI translation" as a category collapse

The objection treats AI translation as a single capability. It isn't — and the relevant question for any specific entry isn't "was this AI-translated" but "what was the workflow, what was verified, what wasn't, and how is the gap disclosed."

The platform's extraction workflow for agent-pipeline entries:

• An AI agent locates the paper through public bibliographic indexes (PubMed, Semantic Scholar, journal sites, institutional archives)
• Where full text is accessible, the agent extracts structured content (methods, results, discussion) with verbatim numerical reporting
• Where full text is paywalled, the agent reconstructs from the abstract + citation network in companion papers + author-group adjacent publications — flagged explicitly
• Per-section confidence notes accompany every translation indicating which content was directly verified vs reconstructed
• The MDX frontmatter carries explicit provenance: translatedFromLanguage, originalTitle (in source language), translatedBy (specifying agent-pipeline pass + date), translationDate

This workflow is more transparent than what most English-language secondary sources do when referencing Russian or Croatian primary literature. The typical pattern in English-language peptide writing is a chain of "Khavinson 2003 showed that telomerase…" citations that have themselves never read the Russian original; the reader has no way to know that the chain ends at a secondary citation rather than a primary source. The AI-extraction entries are at least honest about where the gap is.

2. The accuracy question is testable

The objection implies AI translations are inaccurate. The right way to evaluate this is to check the testable claims. For numerical content — sample sizes, doses, percentages, effect sizes, p-values — verbatim verification against the source is straightforward. If the agent claims "n=80 outbred male LIO rats, 4 arms x 20" and the abstract or paper body says the same, that's verified.

For interpretive content — what the authors think the result means, what limitations they acknowledge, what unresolved questions they raise — translation is harder. Tone, hedging language, and framing nuance can shift across translations. The platform's policy acknowledges this in the per-section confidence notes; methods and results sections are typically high-confidence (the content is more directly verifiable); discussion sections carry lower confidence flags because the interpretive content is more translation-sensitive.

For Russian-language clinical literature specifically, the alternative isn't English-language certainty. The alternative is either (a) read the Russian directly, which most English-speaking readers can't, (b) trust a secondary English citation that may itself be imperfect, or (c) treat the literature as inaccessible and ignore it. Option (c) is the dominant English-language pattern and it produces a systematic blind spot — the Khavinson, Ashmarin, and Levitskaya programs have produced 40+ years of primary-source work that English-language peptide writing mostly summarizes by repeating each other's summaries.

3. The provenance discipline is what makes the entries useful

What the platform commits to with every agent-extraction entry:

• The translation pass is dated. Anyone reviewing the entry knows when the extraction was done and which agent pipeline produced it.
• The source-access status is named. Paywalled body text is flagged explicitly. The reader knows what was directly verifiable vs reconstructed.
• The confidence per section is graded. Methods + results sections that are well-verified carry "high confidence" notes. Discussion sections reconstructed from citation networks carry "medium confidence" notes. The reader can weight content accordingly.
• The link to the source is preserved. The DOI / PubMed link is in the frontmatter; anyone wanting to verify can go to the source.
• Updates are versioned. If a credentialed re-translation pass replaces an abstract-only extraction with verbatim body text, the entry updates with a new translation date and the improved content lifts in via the standard sync pipeline.

This is genuinely more transparent than the alternative — a credentialed human translator producing a 200-word English summary with no version history, no per-section confidence, and no link back to the source. Most published English summaries of Russian peptide literature are exactly this lower-transparency case.

Where the objection has a real point

AI translation is not perfect. The platform's entries flag this in the translator-confidence notes. Specific categories of risk:

• Numerical OCR errors in paywalled-source-PDF extraction. The agent may misread "2.7" as "27" if the source PDF has degraded scan quality. Mitigated by cross-checking against multiple independent indexes where available.
• Tone / hedging loss in translation. Russian academic prose has hedging conventions that English translation can flatten. The discussion-section confidence notes flag this.
• Idiomatic mistranslation in methods descriptions. Specific assay conventions or statistical-testing conventions in Russian psychiatric or neurological literature may translate imprecisely. Methods-section confidence notes acknowledge this.
• Citation-network reconstruction, when used, is inferred. If full body text is not accessible and the agent reconstructs the methods from companion papers using the same paradigm, the resulting description is inferred rather than verbatim. The confidence note flags this.

All of these are real risks. None of them are unique to AI translation — human translators face the same trade-offs. The platform's response is provenance transparency: every entry surfaces these issues explicitly so the reader can weight the content.

Where the objection loses the thread

The collapse from "AI translation has known limitations" to "AI-translated research isn't trustworthy" is the over-correction. The right framing isn't "trust AI translation unconditionally" or "reject AI translation." It's "read the confidence notes, check the source where possible, and weight the content per the disclosed transparency."

For the platform, this is the alternative to the dominant English-language pattern (ignore the Russian literature because we can't read it). The Khavinson, Ashmarin, and Sikiric work is real evidence; making it accessible with explicit confidence notes is more useful than continuing to leave it inaccessible.

The right framing: provenance discipline + verifiable numerics + explicit confidence notes is the workflow that makes any translation — AI or human — trustworthy enough to publish. What disqualifies a translation is hidden workings, not the tool used in the first draft.

See the methodology page section 04 on translation provenance for the operational rules the platform follows. The peptide-specific entries (Zozulya 2008, Kaplan 1996, Levitskaya 2008, Manchenko 2010, Anisimov-Khavinson 2001, Anisimov 2002 colon-cancer, Khavinson Morozov 2003) all carry these provenance details in their frontmatter and confidence notes.